Bardoxolone Methyl Continues to Aid Alport Patients with Kidney Disease, New Data Shows

New results from the Phase 2/3 CARDINAL trial continue to support the benefits of bardoxolone methyl in improving kidney function in people with chronic kidney disease (CKD) due to Alport syndrome. Data from a new analysis of the trial’s Phase 2 part show that significant improvements to the kidneys…

Kidney Function Decline May Not Be Good Indicator of Trial Outcomes in Alport Syndrome Patients, Study Suggests

The rate at which patients with Alport syndrome lose their kidney function varies widely between patients and even within the same individual, according to a study in the Canadian Journal of Kidney Health and Disease. This insight is crucial when studying potential interventions in clinical trials, which tend to observe…